$4.8
+0.01
(+0.21%)▲
Insights on Wave Life Sciences Ltd
Revenue is down for the last 2 quarters, 49.21M → 29.05M (in $), with an average decrease of 41.0% per quarter
Netprofit is down for the last 2 quarters, 7.25M → -16.25M (in $), with an average decrease of 324.2% per quarter
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 34.5%
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 268.7%
2.92%
Downside
Day's Volatility :4.12%
Upside
1.23%
34.38%
Downside
52 Weeks Volatility :58.93%
Upside
37.42%
Period | Wave Life Sciences Ltd | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 0.84% | -0.7% | 0.0% |
6 Months | -14.77% | 6.6% | 0.0% |
1 Year | 12.18% | 3.7% | -1.5% |
3 Years | -19.5% | 14.0% | -21.8% |
Market Capitalization | 643.2M |
Book Value | $0.33 |
Earnings Per Share (EPS) | -0.54 |
PEG Ratio | 0.0 |
Wall Street Target Price | 13.0 |
Profit Margin | -50.76% |
Operating Margin TTM | -64.3% |
Return On Assets TTM | -20.17% |
Return On Equity TTM | -1118.17% |
Revenue TTM | 113.3M |
Revenue Per Share TTM | 1.07 |
Quarterly Revenue Growth YOY | 2245.1% |
Gross Profit TTM | -73.6M |
EBITDA | -63.0M |
Diluted Eps TTM | -0.54 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.01 |
EPS Estimate Next Year | -1.07 |
EPS Estimate Current Quarter | -0.23 |
EPS Estimate Next Quarter | -0.2 |
What analysts predicted
Upside of 170.83%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 14.4M | ↑ 289.15% |
Net Income | -146.7M | ↑ 43.73% |
Net Profit Margin | -1.0K% | ↑ 1737.29% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 16.0M | ↑ 10.89% |
Net Income | -179.5M | ↑ 22.4% |
Net Profit Margin | -1.1K% | ↓ 105.61% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 20.1M | ↑ 25.61% |
Net Income | -149.9M | ↓ 16.48% |
Net Profit Margin | -746.68% | ↑ 376.36% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 41.0M | ↑ 104.03% |
Net Income | -122.2M | ↓ 18.45% |
Net Profit Margin | -298.42% | ↑ 448.26% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.6M | ↓ 91.09% |
Net Income | -161.8M | ↑ 32.38% |
Net Profit Margin | -4.4K% | ↓ 4136.3% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 113.3M | ↑ 3005.1% |
Net Income | -57.5M | ↓ 64.46% |
Net Profit Margin | -50.76% | ↑ 4383.96% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 285.0K | ↓ 24.0% |
Net Income | -39.1M | ↓ 31639.52% |
Net Profit Margin | -13.7K% | ↓ 13755.53% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.2M | ↑ 334.74% |
Net Income | -43.7M | ↑ 11.76% |
Net Profit Margin | -3.5K% | ↑ 10194.7% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.9M | ↑ 943.5% |
Net Income | -24.5M | ↓ 43.89% |
Net Profit Margin | -189.69% | ↑ 3338.07% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 22.1M | ↑ 70.98% |
Net Income | -21.1M | ↓ 13.95% |
Net Profit Margin | -95.47% | ↑ 94.22% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 49.2M | ↑ 122.63% |
Net Income | 7.3M | ↓ 134.36% |
Net Profit Margin | 14.74% | ↑ 110.21% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 29.1M | ↓ 40.96% |
Net Income | -16.3M | ↓ 324.16% |
Net Profit Margin | -55.95% | ↓ 70.69% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 295.9M | ↑ 62.74% |
Total Liabilities | 222.6M | ↑ 429.62% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 284.3M | ↓ 3.95% |
Total Liabilities | 220.5M | ↓ 0.93% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 279.2M | ↓ 1.76% |
Total Liabilities | 196.5M | ↓ 10.91% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 207.0M | ↓ 25.87% |
Total Liabilities | 174.5M | ↓ 11.17% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 146.4M | ↓ 29.28% |
Total Liabilities | 191.5M | ↑ 9.72% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 274.9M | ↑ 87.82% |
Total Liabilities | 227.4M | ↑ 18.78% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 181.5M | ↓ 14.91% |
Total Liabilities | 186.0M | ↑ 2.01% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 146.4M | ↓ 19.35% |
Total Liabilities | 191.5M | ↑ 2.93% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 267.3M | ↑ 82.58% |
Total Liabilities | 302.0M | ↑ 57.71% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 230.0M | ↓ 13.95% |
Total Liabilities | 281.7M | ↓ 6.72% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 199.9M | ↓ 13.07% |
Total Liabilities | 240.4M | ↓ 14.66% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 274.9M | ↑ 37.53% |
Total Liabilities | 227.4M | ↓ 5.39% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -22.9M | ↓ 72.68% |
Investing Cash Flow | -9.9M | ↓ 47.38% |
Financing Cash Flow | 65.1M | ↓ 31.03% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -188.2M | ↑ 723.34% |
Investing Cash Flow | -3.9M | ↓ 60.58% |
Financing Cash Flow | 164.4M | ↑ 152.56% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -116.0M | ↓ 38.38% |
Investing Cash Flow | -1.3M | ↓ 65.85% |
Financing Cash Flow | 154.5M | ↓ 6.0% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -89.0M | ↓ 23.27% |
Investing Cash Flow | -560.0K | ↓ 58.15% |
Financing Cash Flow | 55.8M | ↓ 63.87% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -127.8M | ↑ 43.59% |
Investing Cash Flow | -1.3M | ↑ 124.11% |
Financing Cash Flow | 67.2M | ↑ 20.35% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -25.6M | ↓ 11.02% |
Investing Cash Flow | -501.0K | ↓ 102.04% |
Financing Cash Flow | 17.0K | ↓ 99.97% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -33.4M | ↑ 30.39% |
Investing Cash Flow | -489.0K | ↓ 2.4% |
Financing Cash Flow | 55.0K | ↑ 223.53% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 85.5M | ↓ 355.75% |
Investing Cash Flow | -489.0K | ↑ 0.0% |
Financing Cash Flow | 35.1M | ↑ 63632.73% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -37.3M | ↓ 143.56% |
Investing Cash Flow | -72.0K | ↓ 85.28% |
Financing Cash Flow | 1.8M | ↓ 94.73% |
Sell
Neutral
Buy
Wave Life Sciences Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Wave Life Sciences Ltd | -15.52% | -14.77% | 12.18% | -19.5% | -81.27% |
Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Wave Life Sciences Ltd | NA | NA | 0.0 | -1.01 | -11.18 | -0.2 | NA | 0.33 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Wave Life Sciences Ltd | Buy | $643.2M | -81.27% | NA | -50.76% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
RA Capital Management, LLC
Maverick Capital Ltd
M28 Capital Management LP
Adage Capital Partners Gp LLC
683 Capital Management LLC
BlackRock Inc
Wave Life Sciences Ltd’s price-to-earnings ratio stands at None
Read Morewave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.
Organization | Wave Life Sciences Ltd |
Employees | 266 |
CEO | Dr. Paul B. Bolno M.B.A., M.D. |
Industry | Health Technology |